New Study Bolsters Cologuard’s Performance in Detecting Colorectal Cancer and Ability to Improve Access to Screening

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to New Study Bolsters Cologuard’s Performance in Detecting Colorectal Cancer and Ability to Improve Access to Screening

Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12

October 30, 2015 8:32 AM EDT

Roth Capital maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $12.00 (from $15.00), following the company's 3Q earnings results and guidance. Management introduced 4Q volume guidance of 42k tests. EXAS also introduced 2016 volume and revenue guidance of 240k and... More

Exact Sciences (EXAS) Says New Study Bolsters Cologuard's Performance

October 28, 2015 2:48 PM EDT

Exact Sciences Corp.(NASDAQ: EXAS) today announced that a new peer-reviewed study of Cologuard®, a multi-target stool DNA test (MT-sDNA), confirms its performance across all stages of colorectal cancer and showcases how the at-home test could improve access to screening. In the study of 661 average risk Alaska Native people, Cologuard detected 100% (10/10) of colorectal cancers and 52% (24/46) of significant premalignant lesions (adenomas >1 cm) in people between the ages of 40-85. The detection rate of Cologuard increased to 80% for the largest pre-cancers (>3 cm), which are most likely to progress to cancer. The study, Stool DNA Testing for Screening... More